1 2	Engagement and factors associated with annual anal human papillomavirus screening among sexual and gender minority individuals
3	Jenna Nitkowski, PhD ^{*,1} ; Timothy J. Ridolfi, MD ² ; Sarah J. Lundeen, RN ² ; Anna R.
4	Giuliano, PhD ³ ; Elizabeth Chiao, MD, MPH ⁴ ; Maria E. Fernandez, PhD ⁵ ; Vanessa
5	Schick, PhD ⁶ ; Jennifer S. Smith, PhD ⁷ ; Paige Bruggink, BS ⁸ , Bridgett Brzezinski, MA ¹ ;
6	and Alan G. Nyitray, PhD ^{1,9}
7	¹ Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee,
8	Wisconsin, USA
9	² Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
10	³ Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and
11	Research Institute, Tampa, Florida, USA
12	⁵ MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
13	Department of Health Promotion and Benavioral Sciences, The University of Texas
14 15	⁶ Department of Management, Policy and Community Health, The University of Texas,
15 16	Health Science Center at Houston School of Public Health Houston Texas USA
17	⁷ Gillings School of Global Public Health, University of North Carolina at Chapel Hill.
18	Chapel Hill. North Carolina. USA
19	⁸ Medical College of Wisconsin, Milwaukee, Wisconsin, USA
20	⁹ Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
21	*Oomoon on die eerste op
22	Corresponding author
23	Jenna Nilkowski, PhD Contor for AIDS Intervention Research
24 25	Medical College of Wisconsin
25	2153 N Dr. Martin Luther King Jr. Dr.
27	Milwaukee, WI 53212
28	(414) 955-2126
20	initkowski@mow adu

- 29 jnitkowski@mcw.edu
- 30 ORCID: 0000-0001-5651-8501
- 31
- 32 Abstract word count: 250/250
- 33 Manuscript word count: 2799/3000

34 Abstract

Objectives. Annual screening with a provider has been recommended for groups at 35 highest risk for anal cancer. Anal self-sampling could help address screening barriers, 36 37 yet no studies have examined annual engagement with this method. Methods. The Prevent Anal Cancer Self-Swab Study recruited sexual and gender 38 minority individuals 25 years and over who have sex with men in Milwaukee, Wisconsin 39 to participate in an anal cancer screening study. Participants were randomized to a 40 home or clinic arm. Home-based participants were mailed an anal human 41 42 papillomavirus self-sampling kit at baseline and 12 months, while clinic-based participants were asked to schedule and attend one of five participating clinics at 43 baseline and 12 months. Using Poisson regression, we conducted an intention-to-treat 44 analysis of 240 randomized participants who were invited to screen at both timepoints. 45 **Results.** 58.8% of participants completed annual (median=370 days) anal screening. 46 When stratified by HIV status, persons living with HIV had a higher proportion of home 47 (71.1%) versus clinic (22.2%) annual screening (p<0.001). Non-Hispanic Black 48 participants had a higher proportion of home-based annual anal screening engagement 49 (73.1%) compared to annual clinic screening engagement (31.6%) (p=0.01). Overall, 50 annual screening engagement was significantly higher among participants who had 51 52 heard of anal cancer from an LGBTQ organization, reported "some" prior anal cancer 53 knowledge, preferred an insertive anal sex position, and reported a prior cancer diagnosis. Annual screening engagement was significantly lower for participants 54 reporting a medical condition. 55

- 56 **Conclusions.** Annual screening engagement among those at disproportionate anal
- 57 cancer risk was higher in the home arm.
- 58
- 59 Keywords: anal cancer, sexual and gender minority individuals (SGM), human
- 60 papillomavirus (HPV), self-sampling, screening

61 Introduction

62	Anal cancer disproportionately affects men who have sex with men, particularly if
63	they are living with HIV.(1) Men who have sex with men and trans women living with HIV
64	age 45 and over have a 10-fold higher anal cancer incidence versus the general
65	population.(1, 2) Recently, consensus guidelines for screening those at highest risk for
66	anal cancer have been developed.(2) Although large variation in screening availability
67	and resources inhibits a standardized screening strategy for all settings, initial screening
68	typically consists of anal cytology and human papillomavirus (HPV) testing using
69	clinician-collected anal swabs in addition to a digital anal rectal examination.(2) For
70	negative test results, repeat screening at 12 months is advised.(2)
71	Home-based anal self-sampling is a potential method of anal swab collection to
72	reach individuals for anal precancer screening. Research has shown high acceptability
73	and willingness to use an anal self-sampling test among sexual minority men. (3-5) In
74	the Prevent Anal Cancer Self-Swab Study, a randomized controlled trial which
75	compared home versus clinic anal swabbing,(6) participants were more likely to return a
76	mailed home-based swab than attend a clinic for swabbing by a clinician.(7) Home-
77	based anal screening engagement was especially higher among persons living with HIV
78	and Black individuals, two groups disproportionately affected by anal cancer.(7)
79	To our knowledge, no studies have examined engagement with annual anal HPV
80	DNA self-sampling. The International Anal Neoplasia Society (IANS) anal cancer
81	screening consensus guidelines pertain to clinic-based screening, so home collection
82	testing and intervals have not yet been established. But given that repeat testing is
83	advised for one year later for negative results, it is likely that screening either at home or

in a clinic would be annually. In this research, we present results of engagement with 84 mailed annual home-based anal canal HPV DNA self-sampling and annual clinic-based 85 anal HPV DNA swabbing. We also assess factors associated with annual swabbing. 86 87 Methods Study design and recruitment 88 The Prevent Anal Cancer Self-Swab Study is a randomized controlled trial which 89 examined anal cancer screening among sexual and gender minority individuals in the 90 Milwaukee, Wisconsin area between 2020 and 2023. The protocol has previously been 91 92 published.(6) Participants were recruited via social media ads, flyers distributed in targeted businesses and non-profit organizations, community events, and a voluntary 93 referral program. Eligibility criteria consisted of the following: 25 years of age or over, 94 assigned male sex at birth or transgender gender identity, acknowledgement of sex with 95 men in the last five years or identification as gay or bisexual, and willingness to provide 96 informed consent and comply with the study protocol. Individuals who planned to move 97 within 12 months, reported unwillingness to attend one of the designated study clinics, 98 had a prior diagnosis of anal cancer, or reported use of anticoagulants other than aspirin 99 or non-steroidal anti-inflammatory drugs were excluded. The study activities were 100 approved by the Medical College of Wisconsin Human Protections Committee. 101 After providing informed consent, participants were asked to complete a baseline 102 103 computer-assisted self-interview (CASI) survey. The baseline survey contained questions about attitudes, behaviors, and prior healthcare procedures. Participants were 104 then randomized in a one-to-one allocation to either a home-based or clinic-based arm. 105 106 The overall objective of the study was to evaluate engagement with annual home

107 versus clinic anal HPV DNA screening among sexual and gender minority individuals. Home-based participants were sent an anal self-sampling kit in the mail at baseline and 108 one year later to complete and return via mail. Clinic-based participants were asked to 109 110 attend a clinic appointment at baseline and at 12 months where a clinician collected an anal swab. During the consenting session, participants were told that they will be asked 111 112 to repeat the procedures one year later so no recommendation about annual screening was given by study staff or providers. All participants were asked to attend an initial 113 clinic appointment for a digital anal rectal examination followed by a subsequent 114 115 appointment at 12 months for a high-resolution anoscopy (HRA). Home arm. Participants randomized to the home-based arm were mailed an anal 116 HPV DNA self-sampling kit. The kit consisted of a flocked swab (COPAN Italia S.p.A., 117 118 Brescia, Italy), a vial of standard transport medium (QIAGEN, Germantown, MD, USA), a pair of gloves, illustrated instructions written at a sixth-grade reading level in English 119 or Spanish modeled after published instructions, (8) and instructions and packaging for 120 121 returning the swab. An identical kit was mailed 12 months later. Regardless of whether a participant returned the baseline kit, all participants in the home-based arm were mailed 122 123 a 12-month kit. Study staff contacted participants who did not return the kit via their preferred contact method up to three times. 124 *Clinic arm.* Participants in the clinic arm were asked to attend an appointment at 125

their choice of five area clinics. To mimic real-world conditions, participants were asked
to call and schedule their clinic appointment. At the clinic appointment, biometric
measurements including height, weight, and waist circumference were taken. A highly
experienced clinician then collected an anal swab from the participant and performed a

digital anal rectal examination. The swabs, the standard transport medium, and the 130 swabbing technique instructions were identical in both the home and clinic. Participants 131 were contacted prior to their 12-month anniversary date to schedule the follow-up 132 appointment regardless of attendance at the baseline appointment. Because the 12-133 month clinic appointment and HRA were designed to occur one year after the baseline 134 clinic appointment, some clinic participants opted to combine them. Out of the 71 clinic 135 participants who completed both a 12-month clinic appointment and HRA, 71.8% (n=51) 136 combined these appointments. 137 Between January 2020 and August 2022, a total of 240 participants were 138 randomized to the study (home=120, clinic=120). Study activities were paused between 139 March 2020 and November 2020 due to the COVID-19 pandemic. 140 141 Measures Outcome. Annual anal screening engagement was the outcome. This was coded 142 as a dichotomous variable (1=yes, 0=no) representing whether a participant provided an 143 anal swab at both baseline and 12 months. For home participants, this meant returning 144 both a baseline and 12-month kit. For clinic participants, this meant attending a baseline 145 146 clinic appointment and 12-month clinic appointment/HRA. *Exposures.* The primary exposure of interest was study arm (home-based or 147 clinic-based anal screening). Participant characteristics, behaviors, attitudes, and prior 148

149 health care procedures were all examined as possible exposures. These variables

150 come from the eligibility and baseline participant surveys and consist of age,

151 race/ethnicity, education, marital status, HIV status, preferred anal sex position, sources

of anal cancer awareness, amount of prior anal cancer knowledge, fear of screening,

history of a cancer diagnosis, history of doing a self-examination, history of anal cancer
screening procedures such as anal cytology, smoking status, and ever being diagnosed
with certain medical conditions. We also calculated the 2021 area deprivation index
(ADI) score for each participant's address using the Neighborhood Atlas mapping
function. (9)

For sources of anal cancer awareness, participants were asked "Where have you 158 heard about anal cancer before today? (check all that apply)". Response options 159 160 included: doctor's office, community health worker, public health department, school or university, hospital or research institution, friend or acquaintance, LGBTQ community 161 organization, online, etc. For the medical condition question, participants were asked 162 "Here is a list of medical conditions that may make it harder to use the swab. Has a 163 164 doctor ever said that you have any of the following? (check all that apply)." Response options consisted of the following: arthritis (n=26), carpal tunnel syndrome (n=7), 165 cerebral palsy (n=1), deafness (n=4), diabetes (n=16), fibromyalgia (n=1), chronic lower 166 167 back pain (n=19), motor neuron diseases (n=1), movement disorders (n=4), multiple sclerosis (n=1), obesity (n=34), spina bifida (n=1), spinal cord injury (n=4), stroke (n=2), 168 visual impairment (n=10), other medical condition (n=3), or none of the above (n=151). 169 170 Responses were combined to create a dichotomous variable representing whether a participant reported any medical condition (1=yes, 0=no). 171 172 Statistical analysis

We conducted an intention-to-treat analysis to evaluate engagement and factors associated with annual home and clinic anal HPV DNA screening (n=240). Univariate and multivariable Poisson regression analyses were conducted to evaluate factors

176 associated with annual anal screening engagement. Factors with a p-value of less than 0.25 in bivariate analyses were included in a multivariable regression model. Manual 177 backward elimination was used to remove factors with a p-value greater than 0.05 until 178 179 the remaining factors had a p-value less than or equal to 0.05. Potential confounders were included in the final model. Missing data were handled by pairwise deletion. 180 Response option categories were combined in instances of small cell sizes. Relative 181 risk was calculated using Poisson regression with robust standard errors and the log-182 link function in Stata. We report unadjusted and adjusted relative risk ratios with 95% 183 184 confidence intervals. All analyses were conducted in SPSS 28 (Armonk, NY, USA) and Stata BE 18 (College Station, TX, USA). 185

186 **Results**

Overall, 58.8% (n=141) of 240 randomized participants engaged in annual anal HPV screening with a median of 370 days between screenings. In the home arm, 65.0% of home-based participants engaged in annual screening compared to 52.5% of clinicbased participants (p=0.049) (Figure 1).

Table 1 presents the characteristics of randomized participants stratified by 191 annual screening engagement. The average age was 46 years and ranged from 25 to 192 78 years. Most participants (94.6%) identified as a man, 2.9% as transgender, and 2.5% 193 as non-binary or other. Nearly two-thirds of participants (66.1%) identified as non-194 195 Hispanic White, 18.8% as non-Hispanic Black, 13.0% as Hispanic or Latino/x, and 2.1% as non-Hispanic Other. More than one in four participants (27.1%) were living with HIV, 196 and most reported never or not knowing if they had ever had an anal cytology test 197 198 (75.8%) and little or no prior anal cancer knowledge (78.8%).

199 When stratifying by race/ethnicity (Figure 2), non-Hispanic Black participants had a higher proportion of home-based annual anal screening engagement (73.1%) 200 compared to annual clinic screening engagement (31.6%) (p=0.01). When stratifying by 201 202 HIV status (Figure 2), persons living with HIV had a higher proportion of home-based annual anal screening engagement (71.1%) compared to clinic screening engagement 203 204 (22.2%) (p<0.001). In contrast, HIV-negative participants had nearly equal proportions of engaging in home (62.2%) versus clinic (61.3%) annual screening (p=0.90). 205 Results of univariate and multivariable Poisson regression analyses are 206 207 presented in Table 2. Although not significant, participants in the home-based arm were more likely to engage in annual anal HPV screening (aRR 1.20, 95% CI 0.97 – 1.48) 208 than the clinic arm while controlling for participant characteristics. Participants who 209 210 reported ever being diagnosed with a medical condition were significantly less likely to engage in annual screening (aRR 0.78, 95% CI 0.61 – 0.998) compared to those who 211 did not report a medical condition. 212

213 Participants who reported a preferred insertive anal sex position (aRR 1.51, 95%) CI 1.20 – 1.91) were significantly more likely to engage in annual screening compared 214 215 to versatile participants. Those who reported hearing of anal cancer from an LGBTQ 216 organization, reported some prior anal cancer knowledge, and reported a prior cancer diagnosis were significantly more likely to engage in annual screening. Participants who 217 218 reported previously hearing about anal cancer from an LGBTQ organization were more 219 likely to engage in annual screening (aRR 1.30, 95% CI 1.06 – 1.60) compared to those who had not. Those who reported some prior anal cancer knowledge were more likely 220 221 to screen annually compared to those who had no prior anal cancer knowledge (aRR

1.47, 95% CI 1.09 – 1.99). Participants who had any previous cancer diagnosis were
more likely to engage in annual screening (aRR 1.47 95% CI 1.07 – 2.00) than those
who never had a cancer diagnosis.

225 Discussion

Overall, more than half of randomized participants engaged in annual anal HPV 226 screening. Building upon our previous findings indicating higher engagement in home-227 based anal screening among non-Hispanic Black individuals and those living with HIV at 228 229 baseline, (7) our current data demonstrate similar findings for annual screening. When 230 stratifying by race/ethnicity, non-Hispanic Black participants had over twice the proportion of engaging in home-based annual screening (73.1%) versus clinic-based 231 annual screening (31.6%) (p=0.01). Since Black sexual minority men are less likely to 232 233 report clinic-based anal cancer screening. (10) home sampling may be a way to increase screening engagement. When stratified by HIV status, 71.1% of persons living with HIV 234 completed annual home-based anal screening compared to just 22.2% who engaged in 235 236 annual clinic screening (p<0.001). One possible explanation for this finding is appointment fatigue, which individuals living with HIV may experience due to repeated 237 238 tests and procedures.(11)

We also found that those who had ever been diagnosed with a medical condition were less likely to engage in annual screening, either in the home or clinic. This suggests that managing a chronic condition may be a barrier to screening engagement. Thus, mailed home-based anal self-sampling may be a potential way to ease the burden of managing a chronic condition and increase screening engagement. Participants who had ever done a self-exam (such as for testicular, breast, or skin

cancer) were significantly more likely to engage in annual screening in univariate but not
 multivariable analysis, due to adjusting for factors like prior cancer diagnosis as well as
 prior anal cancer knowledge and sources.

Anal cancer knowledge and information sources were significantly associated 248 with higher annual screening engagement. Participants who reported some amount of 249 250 prior anal cancer knowledge and those who reported hearing about anal cancer from an LGBTQ organization were more likely to engage in annual screening. This suggests that 251 252 LGBTQ organizations may be important channels to increase knowledge and 253 awareness of anal cancer among sexual and gender minority individuals. Notably, knowledge among gay and bisexual men that HPV causes anal cancer is low (12). 254 Campaigns to increase anal cancer knowledge and annual screening engagement may 255 256 partner with LGBTQ organizations as an important source of information. Although provider recommendation is strongly associated with increased cancer screening 257 uptake (13, 14), including anal cancer (15), we found no association between annual 258 259 screening and hearing about anal cancer from a doctor's office. However, hearing about anal cancer in a doctor's office is different than receiving a doctor's recommendation for 260 261 screening.

Participants who reported a preference for a primarily insertive anal sex position were less likely to engage in annual anal screening compared to participants who reported a preference for versatile anal sex. While the reasons for this finding are unclear and may warrant future research, it may be due to stigma associated with being a receptive anal sex partner or "bottom" (16, 17). Gay and bisexual men who report less anal sex stigma have greater comfort with discussing anal sex with a health care

provider and are more likely to engage in anal screening.(18) No significant differences
in annual screening engagement were observed between cisgender men and non-cis
gender persons, although only 13 non-cisgender participants were randomized to the
study.

272 Limitations

This research consisted of participants who chose to enroll in a randomized 273 clinical trial about anal cancer screening. These individuals may differ from those who 274 275 did not or would not choose to participate in this type of study. Thus, the findings from 276 this research may not be representative of all sexual minority men or trans persons. It is 277 also important to note that participants were not *encouraged* by study staff or study health care providers to attend annual screening. Participants were simply told by study 278 279 staff during the consenting session that they will be asked to repeat the procedures one year later. Consensus screening guidelines were also released after the study ended. 280 While we asked participants whether they had received anal cancer screening 281 282 procedures such as anal cytology and high-resolution anoscopy, we were not able to assess the quality of those procedures. Previous research has shown that having a 283 284 negative healthcare experience can affect future healthcare engagement. (19) Finally, the medical condition question asked whether participants had ever been diagnosed so 285 it does not capture whether they currently still have that condition. Future research with 286 287 larger sample sizes of those with medical conditions can hopefully refine this finding.

288 Conclusion

289 This study evaluated annual anal HPV screening engagement in the home and 290 clinic. We found higher annual engagement with mailed home-based self-sampling

- 291 compared to clinician swabbing, particularly among those living with HIV and non-
- 292 Hispanic Black participants. Anal cancer education and its sources, such as LGBTQ
- organizations, may also play a role in increasing annual screening engagement. These
- ²⁹⁴ findings underscore the importance of targeted educational efforts and provision of
- 295 accessible screening methods in increasing anal cancer screening engagement,
- ²⁹⁶ particularly among groups disproportionately affected by anal cancer.

Acknowledgements 298

299	Thank you to the study participants, the Prevent Anal Cancer community
300	advisory board, and the PAC Study Team (Cameron Liebert, Christopher Ajala, Madison
301	Humphry, Esmeralda Lezama-Ruiz, Maritza Pallo, and Lisa Rein). Thanks to the
302	clinicians who participated in this study: Mary Kay Schuknecht, Kathryn Kerhin, Nickie
303	Gerboth, Dave Wenten, Annie Lakatos, Andrew Petroll, Brian Hilgeman, Leslie
304	Cockerham, Sol del Mar Aldrete Audiffred, Winsome Panton, Christine Hogan, and
305	Janaki Shah. We are grateful to the University of Chicago for help with the anal self-
306	sampling illustrated instructions and to COPAN Italia S.p.A. for donation of some of the
307	swabs used in this study.
308	Data Availability Statement
309	Fully de-identified datasets and data dictionary will be shared with properly
310	trained investigators on the study website within 1 year of study completion after
311	assessment of institutional policies, Medical College of Wisconsin Human Research
312	Protections Program rules, and local, state, and federal laws and regulations.
313	Ethics Approval and Patient Consent
314	Informed consent was obtained from all study participants and study activities
315	were approved by the Medical College of Wisconsin Human Research Protections
316	Committee (protocol #PRO00032999).
317	Declaration of Funding
318	This work was supported by the National Cancer Institute of the National
319	Institutes of Health [R01CA215403 to AGN; NCT Registration Number NCT03489707]

and Clinical and Translational Science Institute grant support [2UL1TR001436]. These 320

- funding entities had no involvement in the design, collection, analysis, or interpretation
- of data, writing of this report, or decision to submit this research for publication. The
- 323 content is solely the responsibility of the authors and does not necessarily represent the
- 324 official views of the National Institutes of Health. COPAN Italia S.p.A. donated some of
- the swabs used in this study.
- 326 **Conflicts of Interest**
- 327 The authors declare no conflicts of interest.

328 **Declaration of generative AI and AI-assisted technologies in the writing process**

- 329 The authors declare no generative AI or AI-assisted technologies in the writing
- 330 process.
- 331

332

References

333 Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. A meta-analysis 1. 334 of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer. 335 2021;148(1):38-47. 336 2. Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, Liu Y, Poynten IM, et al. International Anal 337 Neoplasia Society's consensus guidelines for anal cancer screening. Int J Cancer. 2024. 338 Thompson JA, Reiter PL, McRee AL, Moss JL, Brewer NT. Gay and Bisexual Men's Willingness to 3. 339 Use a Self-Collected Anal Cancer Screening Test. J Low Genit Tract Dis. 2015;19(4):354-61. 340 4. Poon MKL, Wong JPH, Li ATW, Manuba M, Bisignano A, Owino M, et al. HIV-positive MSM's 341 knowledge of HPV and anal cancer self-sampling: A scoping review. Curr Oncol. 2018;25(1):e83-e9. 342 5. Nitkowski J, Giuliano AR, Ridolfi T, Chiao E, Fernandez ME, Schick V, et al. Acceptability of Anal 343 Human Papillomavirus Home Self-Sampling and Clinician Sampling Among Sexual and Gender Minority 344 Individuals In Milwaukee, Wisconsin: The Prevent Anal Cancer Self-Swab Study. LGBT Health. 2023. 345 Nyitray AG, Schick V, Swartz MD, Giuliano AR, Fernandez ME, Deshmukh AA, et al. Rationale and 6. 346 design of the Prevent Anal Cancer Self-Swab Study: a protocol for a randomised clinical trial of home-347 based self-collection of cells for anal cancer screening. BMJ Open. 2021;11(6):e051118. 348 7. Nyitray AG, Nitkowski J, McAuliffe TL, Brzezinski B, Swartz MD, Fernandez ME, et al. Home-based 349 self-sampling vs clinician sampling for anal precancer screening: The Prevent Anal Cancer Self-Swab 350 Study. Int J Cancer. 2023;153(4):843-53. 351 Lampinen TM, Latulippe L, van Niekerk D, Schilder AJ, Miller ML, Anema A, et al. Illustrated 8. 352 instructions for self-collection of anorectal swab specimens and their adequacy for cytological 353 examination. Sex Transm Dis. 2006;33(6):386-8. 354 Applied Population Lab U-M. Neighborhood Atlas 2023 [Available from: 9. 355 https://www.neighborhoodatlas.medicine.wisc.edu/mapping. 356 10. Hicks JT, Hwang LY, Baraniuk S, White M, Chiao EY, Onwuka N, et al. Factors associated with self-357 reported anal cancer screening history in men who have sex with men. Sex Health. 2019;16(1):96-8. 358 Flores D, Leblanc N, Barroso J. Enroling and retaining human immunodeficiency virus (HIV) 11. 359 patients in their care: A metasynthesis of qualitative studies. Int J Nurs Stud. 2016;62:126-36. 360 Wheldon CW, Maness SB, Islam JY, Deshmukh AA, Nyitray AG. Gay and Bisexual Men in the US 12. 361 Lack Basic Information About Anal Cancer. J Low Genit Tract Dis. 2021;25(1):48-52. 362 13. Peterson EB, Ostroff JS, DuHamel KN, D'Agostino TA, Hernandez M, Canzona MR, et al. Impact of 363 provider-patient communication on cancer screening adherence: A systematic review. Prev Med. 364 2016;93:96-105. 365 Sarma EA, Silver MI, Kobrin SC, Marcus PM, Ferrer RA. Cancer screening: health impact, 14. 366 prevalence, correlates, and interventions. Psychol Health. 2019;34(9):1036-72. 367 Vanhaesebrouck A, Pernot S, Pavie J, Lucas ML, Collias L, Pere H, et al. Factors associated with 15. 368 anal cancer screening uptake in men who have sex with men living with HIV: a cross-sectional study. Eur J 369 Cancer Prev. 2020;29(1):1-6. 370 Hernandez AL, Weatherly CS, Burrowes S, Jimenez JL, Gonzalez R, Palefsky JM. "The problem is 16. 371 that our culture is just so messed up about aging." Recruiting older men who have sex with men (MSM) 372 into research studies: an example from a study of aging, HIV, and anal HPV. BMC Med Res Methodol. 373 2022;22(1):296. 374 17. Apaydin KZ, Nguyen A, Panther L, Shtasel DL, Dale SK, Borba CPC, et al. Facilitators of and 375 barriers to high-resolution anoscopy adherence among men who have sex with men: a qualitative study.

376 Sex Health. 2018;15(5):431-40.

Kutner BA, Simoni JM, DeWitt W, Gaisa MM, Sandfort TGM. Gay and Bisexual Men Who Report
 Anal Sex Stigma Alongside Discomfort Discussing Anal Sex with Health Workers Are Less Likely to Have

379 Ever Received an Anal Examination or Anal Swab. LGBT Health. 2022;9(2):103-13.

38019.Schwei RJ, Johnson TP, Matthews AK, Jacobs EA. Perceptions of negative health-care experiences

and self-reported health behavior change in three racial and ethnic groups. Ethn Health. 2017;22(2):156-

382 68.



384

Figure 1. Proportion of participants who engaged in annual anal HPV sampling in the Prevent Anal Cancer Self-Swab Study, Milwaukee, Wisconsin, 2020-2023.

Table 1. Intention-to-treat analysis of randomized participants who completed annual anal human papillomavirus swabbing in the Prevent Anal Cancer Self-Swab Study, Milwaukee, Wisconsin, USA, 2020-2023.

		Total	Completed	Did not complete	
		randomized	annual	annual	
		(n=240)	screening	screening	
			(n=141)	(n=99)	
		n (column %)	n (row %)	n (row %)	р
Age, years	Mean, Range	46.0, 25 – 78	46.8, 25 – 78	44.9, 25 – 74	0.28 ^a
Age, years					0.30 b
25-34		74 (30.8)	40 (54.1)	34 (45.9)	
35-44		42 (17.5)	24 (57.1)	18 (42.9)	
45-54		46 (19.2)	29 (63.0)	17 (37.0)	
55-78		78 (32.5)	48 (61.5)	30 (38.5)	
Gender identity					0.91 ^c
Man		227 (94.6)	134 (59.0)	93 (41.0)	
Trans man or	trans woman	7 (2.9)	4 (57.1)	3 (42.9)	
Non-binary or	other	6 (2.5)	3 (50.0)	3 (50.0)	
Sexual orientati	on				0.47 ^c
Gay		198 (82.8)	120 (60.6)	78 (39.4)	
Bisexual		29 (12.1)	15 (51.7)	14 (48.3)	
Queer		9 (3.8)	4 (44.4)	5 (55.6)	
Other, lesbian	, heterosexual	3 (1.3)	1 (33.3)	2 (66.7)	
Race/ethnicity					0.13 [°]
White, non-His	spanic	158 (66.1)	99 (62.7)	59 (37.3)	
Black, non-His	spanic	45 (18.8)	25 (55.6)	20 (44.4)	
Hispanic or La	atino/x	31 (13.0)	15 (48.4)	16 (51.6)	
Other, non-His	spanic ^d	5 (2.1)	1 (20.0)	4 (80.0)	
Education, years					0.02 ^b
<12		6 (2.5)	3 (50.0)	3 (50.0)	
12		24 (10.0)	12 (50.0)	12 (50.0)	
13-15		64 (26.8)	31 (48.4)	33 (51.6)	
16		44 (18.4)	28 (63.6)	16 (36.4)	
>16		101 (42.3)	67 (66.3)	34 (33.7)	
Marital status					0.29 ^c
Married		38 (16.0)	27 (71.1)	11 (28.9)	
Cohabitating/li	iving together	40 (16.9)	23 (57.5)	17 (42.5)	
Divorced/sepa	arated	13 (5.5)	10 (76.9)	3 (23.1)	
Single with no	steady partner	100 (42.2)	52 (52.0)	48 (48.0)	
Single with ste	eady partner(s)	39 (16.5)	24 (61.5)	15 (38.5)	
Widowed		7 (3.0)	4 (57.1)	3 (42.9)	
ADI score Mea	n, SD	5.9 (2.9)	5.8 (3.0)	5.9 (2.8)	0.80 ^a
Health insuranc	e				0.21
Yes		224 (93.3)	134 (59.8)	90 (40.2)	
No or don't kn	ow	16 (6.7)	7 (43.8)	9 (56.3)	
HIV status					0.13
Negative		175 (72.9)	108 (61.7)	67 (38.3)	
Positive		65 (27.1)	33 (50.8)	32 (49.2)	
Preferred anal s	ex position				0.03 ^c
Versatile		111 (46.8)	60 (54.1)	51 (45.9)	
Insertive		47 (19.8)	36 (76.6)	11 (23.4)	
Receptive		71 (30.0)	40 (56.3)	31 (43.7)	
Never engage	d in anal sex	8 (3.4)	3 (37.5)	5 (62.5)	
Medical condition	on		· · ·		0.10
Yes		85 (36.0)	44 (51.8)	41 (48.2)	

No	151 (64.0)	95 (62.9)	56 (37.1)	
Current smoker	()		()	0.15
Yes	30 (14.1)	15 (50.0)	15 (50.0)	
No	183 (85.9)	117 (63.9)	66 (36.1)	
Heard of anal cancer from		(/	()	
My doctor's office				0.61
Yes	67 (28.0)	41 (61,2)	26 (38.8)	
No	172 (72.0)́	99 (57.6)	73 (42.4)	
A community health worker	()		()	0.12
Yes	20 (8.4)	15 (75.0)	5 (25.0)	
No	219 (91.6)	125 (57.1)	94 (42.9)́	
A friend or acquaintance	()		()	0.26
Yes	61 (25.5)	32 (52.5)	29 (47.5)	
No	178 (74.5)	108 (60.7)	70 (39.3)	
An LGBTQ organization			· · ·	0.02
Yes	68 (28.5)	48 (70.6)	20 (29.4)	
No	171 (71.5)	92 (53.8)	79 (46.2)	
Online	()		· · · ·	0.25
Yes	80 (33.5)	51 (63.7)	29 (36.3)	
No	159 (66.5)	89 (56.0)	70 (44.0)	
Prior anal cancer knowledge			· · ·	0.62 °
Nothing at all	74 (30.8)	41 (55.4)	33 (44.6)	
Alittle	115 (47.9)	66 (57.4)	49 (42.6)	
Some	40 (16.7)	27 (67.5)	13 (32.5)	
Quite a lot	11 (4.6)	7 (63.6)	4 (36.4)	
I am afraid to have anal cancer				0.03
screening for fear of a bad				
result				
Strongly agree or agree	30 (12.6)	12 (40.0)	18 (60.0)	
Strongly disagree or disagree	209 (87.4)	128 (61.2)	81 (38.8)	
Ever been diagnosed with any				0.09
kind of cancer				
Yes	24 (10.1)	18 (75.0)	6 (25.0)	
No	214 (89.9)	122 (57.0)	92 (43.0)	
Ever done a self-exam (e.g. for				0.02
testicular, breast, or skin				
cancer)				
Yes	159 (66.3)	102 (64.2)	57 (35.8)	
No	81 (33.8)	39 (48.1)	42 (51.9)	
Ever had anal cytology test				0.45
Yes	58 (24.2)	38 (65.5)	20 (34.5)	
No	157 (65.4)	88 (56.1)	69 (43.9)	
Don't know	25 (10.4)	15 (60.0)	10 (40.0)	

Abbreviations: ADI, area deprivation index; SD, standard deviation; HIV, human immunodeficiency virus; LGBTQ, lesbian, gay, bisexual, transgender, queer and/or questioning.

Missing: Sexual orientation n=1; race/ethnicity n=1; education n=1; marital status n=3; ADI score n=3; preferred anal sex position n=3; any medical condition n=4; current smoker n=27; heard of anal cancer from my doctor's office n=1; heard of anal cancer from a community health worker n=1; heard of anal cancer from a friend or acquaintance n=1; heard of anal cancer from an LGBTQ community organization n=1; heard of anal cancer online n=1; afraid to have anal cancer screening for fear of a bad result n=1; ever been diagnosed with any kind of cancer n=2.

^a t-test.

^bCochran-Armitage test for trend.

^c Fisher exact test.

^d Other, NH includes Asian, American Indian/Alaskan Native, other, and don't know.



430 ukee, Wisconsin, 2020-2023.

Randomization group 1.0 1.0 Clinic 1.0 1.0 1.0 Home 1.24 (1.00 - 1.54) 1.20 (0.97 - 1.48) Age, years 1.00 (1.00 - 1.01) Race/ethnicity White, non-Hispanic 0.89 (0.66 - 1.18) Hispanic or Latino/x 0.77 (0.53 - 1.13) Other, non-Hispanic 0.32 (0.05 - 1.86) Married 1.0 Cohabitating/living together 0.81 (0.58 - 1.13) Divorced/separated 1.08 (0.75 - 1.55) Single with no steady partner(s) 0.87 (0.63 - 1.09) Widowed 0.80 (0.41 - 1.58) HV status Negative 1.0 Preferred anal sex position Versatile 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 Yes 0.31 (1.00 - 1.74) No
Clinic 1.0 1.0 1.0 Home 1.24 (1.00 - 1.54) 1.20 (0.97 - 1.48) Age, years 1.00 (1.00 - 1.01) Race/ethnicity White, non-Hispanic 1.0 Black, non-Hispanic 0.89 (0.66 - 1.18) Hispanic or Latino/x 0.77 (0.53 - 1.13) Other, non-Hispanic 0.32 (0.05 - 1.86) Marital status Marite status Marite status Marite status Single with no steady partner 0.73 (0.55 - 0.97) Single with steady partner(s) 0.87 (0.63 - 1.19) Widowed 0.80 (0.41 - 1.58) HIV status Negative 1.0 Positive 0.82 (0.63 - 1.07) Versatile 1.0 1.03 (0.79 - 1.33) Neever engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 -
Home 1.24 (1.00 - 1.54) 1.20 (0.97 - 1.48) Age, years 1.00 (1.00 - 1.01) Race/ethnicity White, non-Hispanic 0.89 (0.66 - 1.18) Hispanic or Latino/x 0.77 (0.53 - 1.13) Other, non-Hispanic 0.32 (0.05 - 1.86) Married 1.0 Cohabitating/living together 0.81 (0.58 - 1.13) Married 1.0 Cohabitating/living together 0.81 (0.58 - 1.13) Divorced/separated 1.08 (0.75 - 1.55) Single with a steady partner (0.73 (0.55 - 0.97) Single with a steady partner (0.73 (0.55 - 0.97) Widowed 0.80 (0.41 - 1.58) Weigative 1.0 Preferred anal sex position Versatile 1.0 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 <
Age, years $1.00(1.00 - 1.01)$ Race/ethnicity White, non-Hispanic 1.0 Black, non-Hispanic $0.89(0.66 - 1.18)$ Other, non-Hispanic $0.32(0.05 - 1.63)$ Marital status Marital status Marited 1.0 Cohabitating/living together $0.81(0.58 - 1.13)$ Divorced/separated $1.08(0.75 - 1.55)$ Single with no steady partner $0.73(0.55 - 0.97)$ Single with steady partner(s) $0.87(0.63 - 1.19)$ Wridowed $0.80(0.41 - 1.58)$ HIV status Negative 1.0 1.0 Insertive $1.42(1.12 - 1.79)$ $1.51(1.20 - 1.91)$ Receptive $0.82(0.65 - 1.05)$ $0.78(0.61 - 0.99)$ Never engaged in anal sex $0.69(0.28 - 1.73)$ $0.96(0.39 - 2.39)$ Medical condition No 1.0 Yes $0.78(0.51 - 1.14)$ No 1.0
Race/ethnicity Number of the second se
White, non-Hispanic 1.0 Black, non-Hispanic 0.89 (0.66 - 1.18) Hispanic or Latino/x 0.77 (0.53 - 1.13) Other, non-Hispanic 0.32 (0.05 - 1.86) Marital status Married 1.0 Cohabitating/living together 0.81 (0.58 - 1.13) Divorced/separated 1.08 (0.75 - 1.55) Single with no steady partner 0.73 (0.55 - 0.97) Single with steady partner(s) 0.87 (0.63 - 1.19) Widowed 0.80 (0.41 - 1.58) HIV status Negative 1.0 Positive 0.82 (0.63 - 1.07) Versatile 1.0 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition No 1.0 Yes 0.82 (0.65 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 Ves
Black, non-Hispanic $0.89 (0.66 - 1.18)$ Hispanic or Latino/x $0.77 (0.53 - 1.13)$ Other, non-Hispanic $0.32 (0.05 - 1.86)$ Marital status Married 1.0 Cohabitating/living together $0.81 (0.58 - 1.13)$ Divorced/separated $1.08 (0.75 - 1.55)$ Single with no steady partner 0.73 (0.63 - 1.19) Widowed $0.80 (0.41 - 1.58)$ HIV status Negative 1.0 Positive $0.82 (0.63 - 1.07)$ Preferred anal sex position Versatile 1.0 1.0 1.03 (0.79 - 1.33) Never engaged in anal sex $0.69 (0.28 - 1.73)$ $0.96 (0.39 - 2.39)$ Medical condition Yes $0.78 (0.54 - 1.14)$ No 1.0 1.0 Community health worker Yes $0.78 (0.54 - 1.14)$ No
Hispanic or Latino/x $0.77 (0.53 - 1.13)$ Marital status $0.32 (0.05 - 1.86)$ Marital status Single with no steady partner 0.73 (0.55 - 0.97) Single with no steady partner (S) 0.87 (0.63 - 1.19) Widowed 0.80 (0.41 - 1.58) HIV status Negative 1.0 Positive 0.82 (0.63 - 1.07) Preferred and sex position 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition No 1.0 Yes <td< td=""></td<>
Other, non-Hispanic $0.32 (0.05 - 1.86)$ Married 1.0 Cohabitating/living together $0.81 (0.58 - 1.13)$ Divorced/separated $1.08 (0.75 - 1.55)$ Single with no steady partner $0.73 (0.55 - 0.97)$ Single with no steady partner $0.73 (0.55 - 0.97)$ Single with steady partner $0.73 (0.55 - 0.97)$ Single with steady partner(s) $0.87 (0.63 - 1.19)$ Positive Widowed $0.80 (0.41 - 1.58)$ Positive 0.82 (0.63 - 1.07) Preferred anal sex position 1.0 1.0 Insertive 1.42 (1.12 - 1.79) 1.51 (1.20 - 1.91) Receptive 1.04 (0.80 - 1.36) 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition No 1.0 1.0 Current smoker Yes 0.78 (0.54 - 1.05) 0.78 (0.61 - 0.99) No 1.0 No 1.0 1.0 1.0 <t< td=""></t<>
Marital status 1.0 Married 1.0 Cohabitating/living together 0.81 (0.58 - 1.13) Divorced/separated 1.08 (0.75 - 1.55) Single with no steady partner 0.73 (0.55 - 0.97) Widowed 0.87 (0.63 - 1.19) Widowed 0.80 (0.41 - 1.58) HV status Negative 1.0 Positive 0.82 (0.63 - 1.07) Preferred anal sex position Versatile 1.0 1.0 Insertive 1.42 (1.12 - 1.79) 1.51 (1.20 - 1.91) Receptive 1.04 (0.80 - 1.36) 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition Yes 0.82 (0.65 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 Current smoker Yes 0.78 (0.54 - 1.14) No 1.0 1.0
Married 1.0 Cohabitating/living together 0.81 (0.58 - 1.13) Divorced/separated 1.08 (0.75 - 1.55) Single with no steady partner 0.73 (0.55 - 0.97) Single with steady partner(s) 0.87 (0.63 - 1.19) Widowed 0.80 (0.41 - 1.58) HV status Negative 1.0 Positive 0.82 (0.63 - 1.07) Preferred anal sex position Versatile 1.0 1.0 Insertive 1.42 (1.12 - 1.79) 1.51 (1.20 - 1.91) Receptive 1.04 (0.80 - 1.36) 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition Yes 0.82 (0.65 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 Current smoker Yes 0.78 (0.54 - 1.14) No 1.0 Heard of anal cancer from an LGBTQ <t< td=""></t<>
Cohabitating/living together $0.81 (0.58 - 1.13)$ Divorced/separated $1.08 (0.75 - 1.55)$ Single with no steady partner $0.73 (0.55 - 0.97)$ Single with no steady partner(s) $0.87 (0.63 - 1.19)$ Widowed $0.80 (0.41 - 1.58)$ HIV status Negative 1.0 Positive $0.82 (0.63 - 1.07)$ Preferred anal sex position Versatile 1.0 1.0 Insertive $1.42 (1.12 - 1.79)$ $1.51 (1.20 - 1.91)$ Receptive Never engaged in anal sex $0.69 (0.28 - 1.73)$ $0.96 (0.39 - 2.39)$ Medical condition No 1.0 Yes $0.78 (0.61 - 0.99)$ 1.0 No 1.0 1.0 Vers $0.78 (0.54 - 1.14)$ No No 1.0 1.0 No 1.0 1.0 <tr< td=""></tr<>
Divorced/separated 1.08 (0.75 - 1.55) Single with no steady partner 0.73 (0.55 - 0.97) Single with steady partner(s) 0.87 (0.63 - 1.19) Widowed 0.80 (0.41 - 1.58) HIV status Negative 1.0 Positive 0.82 (0.63 - 1.07) Preferred anal sex position Versatile 1.0 1.0 1.0 Insertive 1.42 (1.12 - 1.79) 1.51 (1.20 - 1.91) Receptive 1.04 (0.80 - 1.36) 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition No 1.0 Yes 0.82 (0.65 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 No 1.0 No Heard of anal cancer from a No Organization No 1.0 No 1.0 1.0 1.0 Heard of anal cancer online
Single with no steady partner Single with steady partner(s) $0.73 (0.55 - 0.97)$ Single with steady partner(s) $0.87 (0.63 - 1.19)$ Widowed $0.80 (0.41 - 1.58)$ HV statusNegative 1.0 Positive $0.82 (0.63 - 1.07)$ Preferred anal sex positionVersatile 1.0 1.0Insertive $1.42 (1.12 - 1.79)$ $1.51 (1.20 - 1.91)$ Receptive $1.04 (0.80 - 1.36)$ $1.03 (0.79 - 1.33)$ Never engaged in anal sex $0.69 (0.28 - 1.73)$ $0.96 (0.39 - 2.39)$ Medical conditionYes $0.82 (0.65 - 1.05)$ $0.78 (0.61 - 0.99)$ No 1.0 1.0 1.0 Current smokerYes $0.82 (0.65 - 1.05)$ $0.78 (0.61 - 0.99)$ No 1.0 1.0 1.0 Heard of anal cancer from a community health workerYes $1.31 (1.00 - 1.74)$ No 1.0 1.0 Heard of anal cancer from an LGBTQ organization $1.31 (1.07 - 1.61)$ $1.30 (1.06 - 1.60)$ No 1.0 1.0 Heard of anal cancer online Yes $1.14 (0.92 - 1.41)$ No 1.0 1.0 1.0 Prior anal cancer knowledge $1.0 (0.80 - 1.34)$ $1.10 (0.85 - 1.43)$
Single with steady partner(s) $0.87 (0.63 - 1.19)$ Widowed $0.80 (0.41 - 1.58)$ HIV status Negative 1.0 Positive $0.82 (0.63 - 1.07)$ Preferred anal sex position Versatile 1.0 1.0 1.0 Insertive $1.42 (1.12 - 1.79)$ $1.51 (1.20 - 1.91)$ Receptive $1.04 (0.80 - 1.36)$ $1.03 (0.79 - 1.33)$ Never engaged in anal sex $0.69 (0.28 - 1.73)$ $0.96 (0.39 - 2.39)$ Medical condition Yes $0.82 (0.65 - 1.05)$ $0.78 (0.61 - 0.99)$ No 1.0 1.0 Current smoker Yes $0.78 (0.54 - 1.14)$ No 1.0 No 1.0 No 1.0 No 1.0 No 1.0 No 1.0 1.0 Heard of anal cancer from an LGBTQ $$
Widowed $0.80 (0.41 - 1.58)$ HIV status $0.80 (0.41 - 1.58)$ Negative 1.0 Positive $0.82 (0.63 - 1.07)$ Preferred anal sex position $0.82 (0.63 - 1.07)$ Versatile 1.0 1.0 Insertive $1.42 (1.12 - 1.79)$ $1.51 (1.20 - 1.91)$ Receptive $1.04 (0.80 - 1.36)$ $1.03 (0.79 - 1.33)$ Never engaged in anal sex $0.69 (0.28 - 1.73)$ $0.96 (0.39 - 2.39)$ Medical condition Yes $0.82 (0.65 - 1.05)$ $0.78 (0.61 - 0.99)$ No 1.0 1.0 Current smoker Yes $0.78 (0.54 - 1.14)$ No 1.0 Heard of anal cancer from a Organization Yes $1.31 (1.07 - 1.61)$ $1.30 (1.06 - 1.60)$ No 1.0 1.0 Heard of anal cancer from an LGBTQ Organization <
HIV status
Negative Positive 1.0 Preferred anal sex position Versatile 1.0 1.0 Insertive 1.42 (1.12 - 1.79) 1.51 (1.20 - 1.91) Receptive 1.04 (0.80 - 1.36) 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition Yes 0.82 (0.65 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 Current smoker Yes 0.78 (0.54 - 1.14) No 1.0 Heard of anal cancer from a community health worker Yes 1.31 (1.00 - 1.74) No 1.0 Heard of anal cancer from an LGBTQ organization Yes 1.31 (1.07 - 1.61) 1.30 (1.06 - 1.60) No 1.0 1.0 No 1.0 No 1.0
Positive $0.82 (0.63 - 1.07)$ Preferred anal sex position 1.0 1.0 Versatile 1.0 1.0 Insertive 1.42 (1.12 - 1.79) 1.51 (1.20 - 1.91) Receptive 1.04 (0.80 - 1.36) 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition Yes 0.82 (0.65 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 Current smoker Yes 0.78 (0.54 - 1.14) No 1.0 Heard of anal cancer from a community health worker Yes 1.31 (1.00 - 1.74) No 1.0 Heard of anal cancer from an LGBTQ organization Yes 1.31 (1.07 - 1.61) 1.30 (1.06 - 1.60) No 1.0 1.0 No 1.0 No 1.0
Preferred anal sex position 1.0 1.0 Versatile 1.0 1.0 Insertive 1.42 (1.12 - 1.79) 1.51 (1.20 - 1.91) Receptive 1.04 (0.80 - 1.36) 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition 1.0 1.0 Yes 0.82 (0.65 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 Current smoker - Yes 0.78 (0.54 - 1.14) No 1.0 Heard of anal cancer from a community health worker Yes 1.31 (1.00 - 1.74) No 1.0 Heard of anal cancer from an LGBTQ organization Yes 1.31 (1.07 - 1.61) 1.30 (1.06 - 1.60) No 1.0 1.0 No 1.0 1.0 No 1.0 No
Versatile 1.0 1.0 1.0 Insertive 1.42 (1.12 - 1.79) 1.51 (1.20 - 1.91) Receptive 1.04 (0.80 - 1.36) 1.03 (0.79 - 1.33) Never engaged in anal sex 0.69 (0.28 - 1.73) 0.96 (0.39 - 2.39) Medical condition $Vers$ 0.82 (0.65 - 1.05) 0.78 (0.61 - 0.99) No 1.0 1.0 1.0 Current smoker $Vers$ 0.78 (0.54 - 1.14) No 1.0 1.0 1.0 Heard of anal cancer from a $0.78 (0.54 - 1.14)$ No 1.0 No 1.0 1.0 Heard of anal cancer from an LGBTQ No 1.0 1.0 No 1.0
Insertive $1.42 (1.12 - 1.79)$ $1.51 (1.20 - 1.91)$ Receptive $1.04 (0.80 - 1.36)$ $1.03 (0.79 - 1.33)$ Never engaged in anal sex $0.69 (0.28 - 1.73)$ $0.96 (0.39 - 2.39)$ Medical condition Yes $0.82 (0.65 - 1.05)$ $0.78 (0.61 - 0.99)$ No 1.0 1.0 1.0 Current smoker Yes $0.78 (0.54 - 1.14)$ $$ Yes $0.78 (0.54 - 1.14)$ $$ No No 1.0 1.0 1.0 Heard of anal cancer from a community health worker $-1.31 (1.00 - 1.74)$ $$ Yes $1.31 (1.00 - 1.74)$ $$ No 1.0 1.0 Heard of anal cancer from an LGBTQ organization $-1.31 (1.07 - 1.61)$ $1.30 (1.06 - 1.60)$ No 1.0 1.0 1.0 Heard of anal cancer online $-1.14 (0.92 - 1.41)$ $$ Yes $1.14 (0.92 - 1.41)$ $$ No 1.0 1.0 Heard of anal cancer knowledge $-1.41 (0.92 - 1.41)$ No 1.0 1.0
Receptive 1.04 ($0.80 - 1.36$) 1.03 ($0.79 - 1.33$) Never engaged in anal sex 0.69 ($0.28 - 1.73$) 0.96 ($0.39 - 2.39$) Medical condition
Never engaged in anal sex $0.69 (0.28 - 1.73)$ $0.96 (0.39 - 2.39)$ Medical condition 1.0 $0.96 (0.39 - 2.39)$ No 1.0 1.0 No 1.0 1.0 Current smoker 1.0 1.0 Yes $0.78 (0.61 - 0.99)$ 1.0 No 1.0 1.0 Heard of anal cancer from a $0.78 (0.54 - 1.14)$ $$ No 1.0 $$ Heard of anal cancer from a $0.98 (0.54 - 1.14)$ $$ No 1.0 $$ Heard of anal cancer from a $0.78 (0.54 - 1.14)$ $$ No 1.0 $$ $$ Heard of anal cancer from an LGBTQ $$ $$ organization $$ 1.0 1.0 Yes $1.14 (0.92 - 1.41)$ $$ $$ No 1.0 1.0 $$ No 1.0 $$ $$ No 1.0 $$ $$ No 1.0 $$ $$ No <td< td=""></td<>
Medical condition $0.82 (0.65 - 1.05)$ $0.78 (0.61 - 0.99)$ No 1.0 1.0 Current smoker 1.0 1.0 Yes $0.78 (0.54 - 1.14)$ $$ No 1.0 1.0 Heard of anal cancer from a $0.78 (0.54 - 1.14)$ $$ No 1.0 $$ Heard of anal cancer from a $0.78 (0.54 - 1.14)$ $$ No 1.0 $$ No 1.0 $$ Heard of anal cancer from an LGBTQ $$ $$ organization $$ $$ Yes $1.31 (1.07 - 1.61)$ $1.30 (1.06 - 1.60)$ No 1.0 1.0 Heard of anal cancer online $$ Yes $1.14 (0.92 - 1.41)$ $$ No 1.0 $$ Nothing at all $1.0 (0.85 - 1.43)$
Yes $0.82 (0.65 - 1.05)$ $0.78 (0.61 - 0.99)$ No 1.0 1.0 Current smoker 1.0 Yes $0.78 (0.54 - 1.14)$ $$ No 1.0 $$ Heard of anal cancer from a community health worker $$ Yes $1.31 (1.00 - 1.74)$ $$ No 1.0 $$ Heard of anal cancer from an LGBTQ organization $$ Yes $1.31 (1.07 - 1.61)$ $1.30 (1.06 - 1.60)$ No 1.0 1.0 Heard of anal cancer online $$ Yes $1.14 (0.92 - 1.41)$ $$ No 1.0 1.0 Prior anal cancer knowledge $$ Nothing at all 1.0 1.0 A little $1.04 (0.80 - 1.34)$ $1.10 (0.85 - 1.43)$
No 1.0 1.0 1.0 Current smoker 1.0 1.0 Yes 0.78 (0.54 - 1.14) No 1.0 Heard of anal cancer from a community health worker Yes 1.31 (1.00 - 1.74) No 1.0 Heard of anal cancer from an LGBTQ organization 1.0 Yes 1.31 (1.07 - 1.61) 1.30 (1.06 - 1.60) No 1.0 1.0 Heard of anal cancer online No 1.0 1.0 No 1.0 1.0
Current smoker 1.0 1.0 Yes $0.78 (0.54 - 1.14)$ No 1.0 Heard of anal cancer from a community health worker Yes $1.31 (1.00 - 1.74)$ No 1.0 Heard of anal cancer from an LGBTQ organization 1.0 Yes 1.31 (1.07 - 1.61) 1.30 (1.06 - 1.60) No 1.0 1.0 Heard of anal cancer online Yes 1.14 (0.92 - 1.41) No 1.0 Prior anal cancer knowledge 1.0 Nothing at all 1.0 1.0 A little 1.04 (0.80 - 1.34) 1.10 (0.85 - 1.43)
Yes $0.78 (0.54 - 1.14)$ No 1.0 Heard of anal cancer from a 1.0 community health worker $1.31 (1.00 - 1.74)$ Yes $1.31 (1.00 - 1.74)$ No 1.0 Heard of anal cancer from an LGBTQ -1.0 Heard of anal cancer from an LGBTQ -1.0 Yes $1.31 (1.07 - 1.61)$ $1.30 (1.06 - 1.60)$ No 1.0 1.0 Heard of anal cancer online -1.0 1.0 Yes $1.14 (0.92 - 1.41)$ -1.0 No 1.0 1.0 Prior anal cancer knowledge 1.0 1.0 Nothing at all $1.0 (0.80 - 1.34)$ $1.10 (0.85 - 1.43)$
No 1.0 Heard of anal cancer from a community health worker 1.31 (1.00 - 1.74) Yes 1.31 (1.00 - 1.74) No 1.0 Heard of anal cancer from an LGBTQ organization Yes 1.31 (1.07 - 1.61) 1.30 (1.06 - 1.60) No 1.0 1.0 Heard of anal cancer online Yes 1.14 (0.92 - 1.41) No 1.0 Prior anal cancer knowledge 1.0 1.0 Nothing at all 1.0 (0.85 - 1.43) 1.10 (0.85 - 1.43)
Heard of anal cancer from a community health worker 1.31 (1.00 - 1.74) Yes 1.31 (1.00 - 1.74) No 1.0 Heard of anal cancer from an LGBTQ organization Yes 1.31 (1.07 - 1.61) 1.30 (1.06 - 1.60) No 1.0 1.0 Heard of anal cancer online Yes 1.14 (0.92 - 1.41) No 1.0 Prior anal cancer knowledge 1.0 Nothing at all 1.0 1.0 A little 1.04 (0.80 - 1.34) 1.10 (0.85 - 1.43)
community health worker Yes $1.31 (1.00 - 1.74)$ $$ No 1.0 $$ 1.0 Heard of anal cancer from an LGBTQ organization $$ Yes $1.31 (1.07 - 1.61)$ $1.30 (1.06 - 1.60)$ No 1.0 1.0 Heard of anal cancer online $$ Yes $1.14 (0.92 - 1.41)$ $$ No 1.0 $$ Prior anal cancer knowledge 1.0 1.0 Nothing at all $1.0 (0.85 - 1.43)$ $1.10 (0.85 - 1.43)$
Yes $1.31 (1.00 - 1.74)$ No 1.0 1.0 Heard of anal cancer from an LGBTQ 1.0 organization $1.31 (1.07 - 1.61)$ $1.30 (1.06 - 1.60)$ No 1.0 1.0 Heard of anal cancer online 1.0 1.0 Yes $1.14 (0.92 - 1.41)$ $$ No 1.0 1.0 Prior anal cancer knowledge 1.0 1.0 Nothing at all 1.0 1.0 A little $1.04 (0.80 - 1.34)$ $1.10 (0.85 - 1.43)$
No1.0Heard of anal cancer from an LGBTQ organization Yes1.31 (1.07 - 1.61)1.30 (1.06 - 1.60)No1.01.01.0Heard of anal cancer online Yes1.14 (0.92 - 1.41)No1.01.0Prior anal cancer knowledge Nothing at all A little1.01.01.04 (0.80 - 1.34)1.10 (0.85 - 1.43)
Heard of anal cancer from an LGBTQ organization 1.31 (1.07 - 1.61) 1.30 (1.06 - 1.60) Yes 1.0 1.0 No 1.0 1.0 Heard of anal cancer online $1.14 (0.92 - 1.41)$ Yes 1.14 (0.92 - 1.41) No 1.0 1.0 Prior anal cancer knowledge 1.0 1.0 Nothing at all 1.0 (0.85 - 1.43) 1.10 (0.85 - 1.43)
organization 1.31 (1.07 - 1.61) 1.30 (1.06 - 1.60) No 1.0 1.0 Heard of anal cancer online 1.14 (0.92 - 1.41) Yes 1.14 (0.92 - 1.41) No 1.0 1.0 Prior anal cancer knowledge 1.0 1.0 Nothing at all 1.0 1.0 A little 1.04 (0.80 - 1.34) 1.10 (0.85 - 1.43)
Yes $1.31 (1.07 - 1.61)$ $1.30 (1.06 - 1.60)$ No 1.0 1.0 Heard of anal cancer online $1.14 (0.92 - 1.41)$ $$ Yes $1.14 (0.92 - 1.41)$ $$ No 1.0 1.0 Prior anal cancer knowledge 1.0 1.0 Nothing at all 1.0 1.0 A little $1.04 (0.80 - 1.34)$ $1.10 (0.85 - 1.43)$
No 1.0 1.0 Heard of anal cancer online 1.14 (0.92 – 1.41) Yes 1.14 (0.92 – 1.41) No 1.0 Prior anal cancer knowledge 1.0 1.0 Nothing at all 1.0 1.0 1.0 A little 1.04 (0.80 – 1.34) 1.10 (0.85 – 1.43)
Heard of anal cancer online $1.14 (0.92 - 1.41)$ No 1.0 Prior anal cancer knowledge 1.0 1.0 Nothing at all $1.0 (0.80 - 1.34)$ $1.10 (0.85 - 1.43)$
Yes 1.14 (0.92 – 1.41) No 1.0 Prior anal cancer knowledge 1.0 1.0 Nothing at all 1.0 1.0 A little 1.04 (0.80 – 1.34) 1.10 (0.85 – 1.43)
No 1.0 Prior anal cancer knowledge 1.0 Nothing at all 1.0 1.0 A little 1.04 (0.80 - 1.34) 1.10 (0.85 - 1.43)
Prior anal cancer knowledge 1.0 1.0 Nothing at all 1.04 (0.80 - 1.34) 1.10 (0.85 - 1.43)
Nothing at all1.01.0A little1.04 (0.80 - 1.34)1.10 (0.85 - 1.43)
A little 1.04 (0.80 – 1.34) 1.10 (0.85 – 1.43)
Some 1.22 (0.90 – 1.64) 1.47 (1.09 – 1.99)
Quite a lot $1.15(0.70 - 1.88)$ $1.10(0.74 - 1.64)$
I am afraid to have anal cancer
screening for fear of a bad result
Strongly agree or agree 0.65 (0.42 – 1.03)
Strongly disagree or disagree 1.0
Ever been diagnosed with cancer
Yes 1.32 (1.02 – 1.70) 1.47 (1.07 – 2.00)

Table 2. Factors associated with annual anal HPV screening engagement in the Prevent Anal Cancer Self-Swab Study, Milwaukee, Wisconsin, 2020-2023 (n=240).

No	1.0	1.0
Ever done a self-examination		
Yes	1.33 (1.03 – 1.72)	
No	1.0	

Abbreviations: RR, relative risk; CI, confidence interval; HIV, human immunodeficiency virus; LGBTQ, lesbian, gay, bisexual, transgender, gueer and/or guestioning. Bolded variables have 95% CI that do ^a The final multivariable model includes all variables in the table in addition to confounders age,

race/ethnicity, and HIV status.